25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Armata Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Armata Pharmaceuticals Inc together

I guess you are interested in Armata Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Armata Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Armata Pharmaceuticals Inc

I send you an email if I find something interesting about Armata Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Armata Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Armata Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-1.41
Expected worth in 1 year
$-2.48
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-1.07
Return On Investment
-47.4%

For what price can you sell your share?

Current Price per Share
$2.25
Expected price per share
$1.87 - $2.2
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Armata Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$2.25
Intrinsic Value Per Share
$-13.46 - $-8.31
Total Value Per Share
$-14.87 - $-9.72

2.2. Growth of Armata Pharmaceuticals Inc (5 min.)




Is Armata Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$50.9m$16.3m-$62.7m-135.2%

How much money is Armata Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.3m-$15.6m$5.3m51.4%
Net Profit Margin-972.3%-1,525.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Armata Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#928 / 954

Most Revenue
#542 / 954

Most Profit
#568 / 954

Most Efficient
#707 / 954
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Armata Pharmaceuticals Inc?

Welcome investor! Armata Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Armata Pharmaceuticals Inc.

First you should know what it really means to hold a share of Armata Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Armata Pharmaceuticals Inc is $2.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Armata Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Armata Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.41. Based on the TTM, the Book Value Change Per Share is $-0.27 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Armata Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-6.7%-0.31-13.7%-0.41-18.3%-0.25-11.1%-0.16-7.1%
Usd Book Value Change Per Share-0.62-27.4%-0.27-11.8%-0.40-17.8%-0.10-4.2%-0.04-1.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.62-27.4%-0.27-11.8%-0.40-17.8%-0.10-4.2%-0.04-1.9%
Usd Price Per Share2.37-3.14-1.76-3.34-2.44-
Price to Earnings Ratio-3.91--0.61--1.48--3.90--3.36-
Price-to-Total Gains Ratio-3.84--3.10--6.27--4.84--13.34-
Price to Book Ratio-1.68--2.87--0.67-2.24-3.46-
Price-to-Total Gains Ratio-3.84--3.10--6.27--4.84--13.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.25
Number of shares444
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.27-0.10
Usd Total Gains Per Share-0.27-0.10
Gains per Quarter (444 shares)-118.37-42.40
Gains per Year (444 shares)-473.50-169.60
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-473-4830-170-180
20-947-9560-339-350
30-1420-14290-509-520
40-1894-19020-678-690
50-2367-23750-848-860
60-2841-28480-1018-1030
70-3314-33210-1187-1200
80-3788-37940-1357-1370
90-4261-42670-1526-1540
100-4735-47400-1696-1710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%5.035.00.012.5%13.096.00.011.9%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%12.027.01.030.0%34.071.04.031.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%3.00.0106.02.8%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%12.027.01.030.0%34.071.04.031.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Armata Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.617-0.267-57%-0.400-35%-0.095-85%-0.043-93%
Book Value Per Share---1.409-1.162-18%0.451-412%0.401-451%0.354-498%
Current Ratio--0.1890.496-62%1.008-81%2.579-93%2.814-93%
Debt To Asset Ratio--1.5191.426+6%0.834+82%0.717+112%0.586+159%
Debt To Equity Ratio----0%2.447-100%0.997-100%1.101-100%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.151-0.309+104%-0.411+171%-0.250+65%-0.161+6%
Free Cash Flow Per Share---0.254-0.261+2%-0.381+50%-0.227-11%-0.153-40%
Free Cash Flow To Equity Per Share---0.256-0.020-92%-0.011-96%0.024-1161%0.007-3574%
Gross Profit Margin--1.0000.998+0%1.0000%1.000+0%0.973+3%
Intrinsic Value_10Y_max---8.309--------
Intrinsic Value_10Y_min---13.460--------
Intrinsic Value_1Y_max---0.644--------
Intrinsic Value_1Y_min---1.203--------
Intrinsic Value_3Y_max---2.079--------
Intrinsic Value_3Y_min---3.761--------
Intrinsic Value_5Y_max---3.687--------
Intrinsic Value_5Y_min---6.463--------
Market Cap81411975.000-5%85753947.000128602692.625-33%63772713.750+34%124030021.225-31%89749356.763-4%
Net Profit Margin----9.7230%-15.2530%-362.0030%-208.1200%
Operating Margin----9.0140%-15.4640%-390.8680%-214.2140%
Operating Ratio---4.714-100%10.813-100%389.242-100%219.155-100%
Pb Ratio-1.597+5%-1.682-2.872+71%-0.668-60%2.236-175%3.457-149%
Pe Ratio-3.713+5%-3.911-0.611-84%-1.477-62%-3.9040%-3.360-14%
Price Per Share2.250-5%2.3703.135-24%1.763+34%3.344-29%2.439-3%
Price To Free Cash Flow Ratio-2.212+5%-2.330-3.020+30%-1.196-49%-4.970+113%-5.094+119%
Price To Total Gains Ratio-3.645+5%-3.839-3.103-19%-6.271+63%-4.838+26%-13.342+247%
Quick Ratio--0.1640.443-63%0.770-79%2.384-93%2.541-94%
Return On Assets---0.056-0.090+62%-0.145+160%-0.117+110%-0.136+143%
Return On Equity----0%-0.3140%-0.1910%-0.2130%
Total Gains Per Share---0.617-0.267-57%-0.400-35%-0.095-85%-0.043-93%
Usd Book Value---50973000.000-46412250.000-9%16321000.000-412%13650700.000-473%12359025.000-512%
Usd Book Value Change Per Share---0.617-0.267-57%-0.400-35%-0.095-85%-0.043-93%
Usd Book Value Per Share---1.409-1.162-18%0.451-412%0.401-451%0.354-498%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.151-0.309+104%-0.411+171%-0.250+65%-0.161+6%
Usd Free Cash Flow---9203000.000-10521500.000+14%-13772750.000+50%-8428100.000-8%-5636225.000-39%
Usd Free Cash Flow Per Share---0.254-0.261+2%-0.381+50%-0.227-11%-0.153-40%
Usd Free Cash Flow To Equity Per Share---0.256-0.020-92%-0.011-96%0.024-1161%0.007-3574%
Usd Market Cap81411975.000-5%85753947.000128602692.625-33%63772713.750+34%124030021.225-31%89749356.763-4%
Usd Price Per Share2.250-5%2.3703.135-24%1.763+34%3.344-29%2.439-3%
Usd Profit---5481000.000-10340750.000+89%-15660750.000+186%-9025800.000+65%-5610050.000+2%
Usd Revenue---623500.000-100%1013000.000-100%614619.450-100%331459.725-100%
Usd Total Gains Per Share---0.617-0.267-57%-0.400-35%-0.095-85%-0.043-93%
 EOD+2 -6MRQTTM+11 -19YOY+16 -145Y+11 -2010Y+11 -22

3.3 Fundamental Score

Let's check the fundamental score of Armata Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.713
Price to Book Ratio (EOD)Between0-1-1.597
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.164
Current Ratio (MRQ)Greater than10.189
Debt to Asset Ratio (MRQ)Less than11.519
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.056
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Armata Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.470
Ma 20Greater thanMa 502.324
Ma 50Greater thanMa 1002.324
Ma 100Greater thanMa 2002.470
OpenGreater thanClose2.199
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Fundamental data was last updated by Penke on 2024-11-22 12:32:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Armata Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-972.3%+972.3%
TTM-972.3%YOY-1,525.3%+553.0%
TTM-972.3%5Y-36,200.3%+35,228.0%
5Y-36,200.3%10Y-20,812.0%-15,388.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--120.2%+120.2%
TTM-972.3%-210.7%-761.6%
YOY-1,525.3%-219.8%-1,305.5%
5Y-36,200.3%-348.0%-35,852.3%
10Y-20,812.0%-473.2%-20,338.8%
4.3.1.2. Return on Assets

Shows how efficient Armata Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • -5.6% Return on Assets means that Armata Pharmaceuticals Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Armata Pharmaceuticals Inc:

  • The MRQ is -5.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.6%TTM-9.0%+3.5%
TTM-9.0%YOY-14.5%+5.5%
TTM-9.0%5Y-11.7%+2.7%
5Y-11.7%10Y-13.6%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.6%-11.0%+5.4%
TTM-9.0%-11.7%+2.7%
YOY-14.5%-11.3%-3.2%
5Y-11.7%-12.6%+0.9%
10Y-13.6%-14.3%+0.7%
4.3.1.3. Return on Equity

Shows how efficient Armata Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Armata Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-31.4%+31.4%
TTM-5Y-19.1%+19.1%
5Y-19.1%10Y-21.3%+2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.1%+14.1%
TTM--15.8%+15.8%
YOY-31.4%-13.8%-17.6%
5Y-19.1%-18.5%-0.6%
10Y-21.3%-19.2%-2.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Armata Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Armata Pharmaceuticals Inc is operating .

  • Measures how much profit Armata Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-901.4%+901.4%
TTM-901.4%YOY-1,546.4%+645.0%
TTM-901.4%5Y-39,086.8%+38,185.4%
5Y-39,086.8%10Y-21,421.4%-17,665.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--267.8%+267.8%
TTM-901.4%-313.2%-588.2%
YOY-1,546.4%-224.0%-1,322.4%
5Y-39,086.8%-385.5%-38,701.3%
10Y-21,421.4%-498.7%-20,922.7%
4.3.2.2. Operating Ratio

Measures how efficient Armata Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.714-4.714
TTM4.714YOY10.813-6.099
TTM4.7145Y389.242-384.528
5Y389.24210Y219.155+170.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.631-2.631
TTM4.7143.412+1.302
YOY10.8133.299+7.514
5Y389.2424.788+384.454
10Y219.1556.538+212.617
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Armata Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Armata Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.19 means the company has $0.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.189. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.496. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.189TTM0.496-0.306
TTM0.496YOY1.008-0.512
TTM0.4965Y2.579-2.083
5Y2.57910Y2.814-0.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1893.688-3.499
TTM0.4963.875-3.379
YOY1.0084.695-3.687
5Y2.5795.959-3.380
10Y2.8146.274-3.460
4.4.3.2. Quick Ratio

Measures if Armata Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.16 means the company can pay off $0.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.164. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.443. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.164TTM0.443-0.280
TTM0.443YOY0.770-0.327
TTM0.4435Y2.384-1.940
5Y2.38410Y2.541-0.157
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1643.117-2.953
TTM0.4433.444-3.001
YOY0.7704.498-3.728
5Y2.3845.922-3.538
10Y2.5416.414-3.873
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Armata Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Armata Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Armata Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.52 means that Armata Pharmaceuticals Inc assets are financed with 151.9% credit (debt) and the remaining percentage (100% - 151.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 1.519. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.426. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.519TTM1.426+0.092
TTM1.426YOY0.834+0.592
TTM1.4265Y0.717+0.709
5Y0.71710Y0.586+0.131
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5190.354+1.165
TTM1.4260.350+1.076
YOY0.8340.310+0.524
5Y0.7170.366+0.351
10Y0.5860.382+0.204
4.5.4.2. Debt to Equity Ratio

Measures if Armata Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.447-2.447
TTM-5Y0.997-0.997
5Y0.99710Y1.101-0.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.436-0.436
YOY2.4470.378+2.069
5Y0.9970.451+0.546
10Y1.1010.493+0.608
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Armata Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Armata Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -3.91 means the investor is paying $-3.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is -3.713. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.911. Based on the earnings, the company is expensive. -2
  • The TTM is -0.611. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.713MRQ-3.911+0.198
MRQ-3.911TTM-0.611-3.301
TTM-0.611YOY-1.477+0.866
TTM-0.6115Y-3.904+3.293
5Y-3.90410Y-3.360-0.544
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.713-2.169-1.544
MRQ-3.911-2.453-1.458
TTM-0.611-3.147+2.536
YOY-1.477-3.335+1.858
5Y-3.904-6.032+2.128
10Y-3.360-6.597+3.237
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is -2.212. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.330. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.020. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.212MRQ-2.330+0.118
MRQ-2.330TTM-3.020+0.690
TTM-3.020YOY-1.196-1.823
TTM-3.0205Y-4.970+1.950
5Y-4.97010Y-5.094+0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.212-3.020+0.808
MRQ-2.330-3.395+1.065
TTM-3.020-3.650+0.630
YOY-1.196-4.541+3.345
5Y-4.970-8.375+3.405
10Y-5.094-9.277+4.183
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Armata Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.68 means the investor is paying $-1.68 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is -1.597. Based on the equity, the company is expensive. -2
  • The MRQ is -1.682. Based on the equity, the company is expensive. -2
  • The TTM is -2.872. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.597MRQ-1.682+0.085
MRQ-1.682TTM-2.872+1.190
TTM-2.872YOY-0.668-2.204
TTM-2.8725Y2.236-5.109
5Y2.23610Y3.457-1.220
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.5971.860-3.457
MRQ-1.6822.035-3.717
TTM-2.8722.339-5.211
YOY-0.6682.391-3.059
5Y2.2363.666-1.430
10Y3.4574.360-0.903
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Armata Pharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets98,237
Total Liabilities149,210
Total Stockholder Equity-50,973
 As reported
Total Liabilities 149,210
Total Stockholder Equity+ -50,973
Total Assets = 98,237

Assets

Total Assets98,237
Total Current Assets22,389
Long-term Assets75,848
Total Current Assets
Cash And Cash Equivalents 17,141
Net Receivables 2,219
Other Current Assets 3,029
Total Current Assets  (as reported)22,389
Total Current Assets  (calculated)22,389
+/-0
Long-term Assets
Property Plant Equipment 55,867
Goodwill 3,490
Long-term Assets Other 16,491
Long-term Assets  (as reported)75,848
Long-term Assets  (calculated)75,848
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities118,204
Long-term Liabilities31,006
Total Stockholder Equity-50,973
Total Current Liabilities
Short-term Debt 46,351
Accounts payable 1,815
Other Current Liabilities 70,038
Total Current Liabilities  (as reported)118,204
Total Current Liabilities  (calculated)118,204
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)31,006
Long-term Liabilities  (calculated)0
+/- 31,006
Total Stockholder Equity
Common Stock362
Retained Earnings -330,335
Other Stockholders Equity 279,000
Total Stockholder Equity (as reported)-50,973
Total Stockholder Equity (calculated)-50,973
+/-0
Other
Cash and Short Term Investments 17,141
Common Stock Shares Outstanding 36,180
Liabilities and Stockholders Equity 98,237
Net Debt 57,139
Net Working Capital -95,815
Short Long Term Debt Total 74,280



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-31
> Total Assets 
0
0
0
12,100
0
21,000
18,600
17,000
14,400
11,900
21,700
20,000
17,400
30,500
27,800
25,100
21,200
17,300
14,200
9,800
6,700
15,800
12,200
16,200
13,200
11,000
14,200
13,700
38,889
35,348
84,780
87,974
83,311
75,100
73,322
71,038
62,096
62,595
59,651
52,712
50,623
62,314
63,013
57,672
77,116
73,273
67,383
69,965
65,410
60,370
52,423
48,798
51,083
22,985
19,945
17,467
21,618
37,473
31,508
28,474
24,248
22,713
19,184
7,150
5,471
4,077
4,530
11,480
22,070
0
0
22,740
37,947
37,947
31,262
28,419
28,617
28,617
36,372
34,078
31,493
28,261
29,279
26,036
18,195
14,302
15,106
13,781
11,138
14,399
11,720
10,619
11,887
9,617
34,916
29,304
25,451
44,102
49,461
45,675
39,516
52,845
48,281
42,671
69,768
107,765
100,984
92,881
95,834
108,779
101,212
112,761
109,964
120,356
108,313
98,237
98,237108,313120,356109,964112,761101,212108,77995,83492,881100,984107,76569,76842,67148,28152,84539,51645,67549,46144,10225,45129,30434,9169,61711,88710,61911,72014,39911,13813,78115,10614,30218,19526,03629,27928,26131,49334,07836,37228,61728,61728,41931,26237,94737,94722,7400022,07011,4804,5304,0775,4717,15019,18422,71324,24828,47431,50837,47321,61817,46719,94522,98551,08348,79852,42360,37065,41069,96567,38373,27377,11657,67263,01362,31450,62352,71259,65162,59562,09671,03873,32275,10083,31187,97484,78035,34838,88913,70014,20011,00013,20016,20012,20015,8006,7009,80014,20017,30021,20025,10027,80030,50017,40020,00021,70011,90014,40017,00018,60021,000012,100000
   > Total Current Assets 
0
0
0
6,900
0
15,700
13,300
11,700
9,100
6,700
16,300
14,600
12,000
25,000
22,200
19,500
15,800
12,200
9,500
5,300
2,100
11,500
8,200
12,400
9,200
6,800
10,000
9,300
34,588
31,361
39,828
42,185
38,207
30,165
29,861
29,489
21,310
22,597
20,347
14,228
12,923
25,332
26,591
21,632
41,482
37,935
32,115
35,153
30,802
26,370
18,461
15,185
17,608
13,407
10,528
8,235
12,538
28,294
22,396
19,296
15,193
13,283
9,766
5,665
4,294
2,992
4,234
1,620
1,650
0
0
5,310
20,534
20,534
12,983
10,092
7,020
7,020
14,863
12,562
10,016
6,753
7,738
4,561
6,355
2,560
9,244
7,989
5,385
8,743
6,120
5,114
8,408
5,942
14,202
9,934
6,655
25,776
20,684
17,024
10,846
24,039
19,709
14,178
14,995
48,699
41,306
33,245
27,047
38,595
26,834
36,585
19,151
41,717
30,903
22,389
22,38930,90341,71719,15136,58526,83438,59527,04733,24541,30648,69914,99514,17819,70924,03910,84617,02420,68425,7766,6559,93414,2025,9428,4085,1146,1208,7435,3857,9899,2442,5606,3554,5617,7386,75310,01612,56214,8637,0207,02010,09212,98320,53420,5345,310001,6501,6204,2342,9924,2945,6659,76613,28315,19319,29622,39628,29412,5388,23510,52813,40717,60815,18518,46126,37030,80235,15332,11537,93541,48221,63226,59125,33212,92314,22820,34722,59721,31029,48929,86130,16538,20742,18539,82831,36134,5889,30010,0006,8009,20012,4008,20011,5002,1005,3009,50012,20015,80019,50022,20025,00012,00014,60016,3006,7009,10011,70013,30015,70006,900000
       Cash And Cash Equivalents 
0
0
0
1,200
0
6,100
3,600
2,300
500
300
3,000
2,200
1,500
7,200
2,200
3,500
900
200
3,200
1,000
600
1,700
1,700
1,900
600
2,000
5,000
4,100
29,336
27,941
38,831
38,630
34,034
26,582
28,187
25,186
17,023
17,273
17,269
12,606
12,231
24,752
26,118
21,057
41,119
37,381
31,333
34,096
30,423
25,609
17,151
14,122
15,998
12,171
9,280
6,206
11,254
26,045
20,531
16,442
12,862
12,701
9,183
5,216
3,916
2,469
3,974
1,100
860
0
0
4,860
20,355
20,355
12,550
9,786
6,581
6,581
14,351
11,737
9,370
6,173
7,144
3,967
5,711
2,202
8,962
7,725
5,132
8,206
5,798
4,499
8,157
5,535
13,192
8,690
6,033
24,209
19,786
15,885
9,649
22,455
17,536
12,076
10,288
46,408
36,978
25,382
14,852
25,106
12,456
23,958
13,523
37,860
26,405
17,141
17,14126,40537,86013,52323,95812,45625,10614,85225,38236,97846,40810,28812,07617,53622,4559,64915,88519,78624,2096,0338,69013,1925,5358,1574,4995,7988,2065,1327,7258,9622,2025,7113,9677,1446,1739,37011,73714,3516,5816,5819,78612,55020,35520,3554,860008601,1003,9742,4693,9165,2169,18312,70112,86216,44220,53126,04511,2546,2069,28012,17115,99814,12217,15125,60930,42334,09631,33337,38141,11921,05726,11824,75212,23112,60617,26917,27317,02325,18628,18726,58234,03438,63038,83127,94129,3364,1005,0002,0006001,9001,7001,7006001,0003,2002009003,5002,2007,2001,5002,2003,0003005002,3003,6006,10001,200000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,600
3,100
3,046
1,532
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000000000000000001,5323,0463,1003,60000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
1,000
1,300
1,800
1,975
1,355
639
3,264
3,643
2,553
954
3,368
3,368
4,259
2,238
1,170
1,170
7
25
166
8
0
1
404
104
124
611
380
991
290
613
1,498
944
1,874
1,544
2,611
2,060
255
368
317
257
129
7
120
20
0
0
10
8
8
136
27
100
100
0
40
125
14
18
24
644
15
0
0
0
0
0
0
0
0
0
0
0
1,000
0
335
561
1,125
1,168
1,251
2,989
1,236
1,883
1,867
1,936
1,257
8,633
8,497
3,363
1,714
1,242
2,219
2,2191,2421,7143,3638,4978,6331,2571,9361,8671,8831,2362,9891,2511,1681,12556133501,0000000000000015644241814125400100100271368810002012071292573173682552,0602,6111,5441,8749441,4986132909913806111241044041081662571,1701,1702,2384,2593,3683,3689542,5533,6433,2646391,3551,9751,8001,3001,000300000000000000000000000000
       Other Current Assets 
0
0
0
5,700
0
9,600
9,700
9,400
8,600
6,400
13,300
12,400
10,500
17,800
20,000
16,000
14,900
12,000
6,300
4,300
1,500
9,800
6,500
10,500
8,300
3,800
100
300
231
533
358
291
530
1,030
720
935
919
1,065
840
452
692
573
448
409
355
554
781
653
275
637
699
683
619
946
635
531
340
375
321
243
271
327
215
132
121
394
253
400
770
0
0
440
0
171
297
279
0
339
512
785
521
566
576
570
619
343
282
264
253
537
322
615
251
407
1,010
1,244
622
567
898
804
636
459
1,005
851
1,718
1,055
2,445
5,996
10,259
12,232
5,745
4,130
2,265
2,143
3,256
3,029
3,0293,2562,1432,2654,1305,74512,23210,2595,9962,4451,0551,7188511,0054596368048985676221,2441,01040725161532253725326428234361957057656652178551233902792971710440007704002533941211322153272712433213753405316359466196836996372756537815543554094485736924528401,0659199357201,0305302913585332313001003,8008,30010,5006,5009,8001,5004,3006,30012,00014,90016,00020,00017,80010,50012,40013,3006,4008,6009,4009,7009,60005,700000
   > Long-term Assets 
0
0
0
5,200
0
5,300
5,300
5,300
5,300
5,200
5,400
5,400
5,400
5,500
5,600
5,600
5,400
5,100
4,700
4,500
4,600
4,300
4,000
3,800
4,000
4,200
4,200
4,400
4,301
3,987
44,952
45,789
45,104
44,935
43,461
41,549
40,786
39,998
39,304
38,484
37,700
36,982
36,422
36,040
35,634
35,338
35,268
34,812
34,608
34,000
33,962
33,613
33,475
9,578
9,417
9,232
9,080
9,179
9,112
9,178
9,055
9,430
9,418
1,485
1,177
1,085
296
9,860
20,420
0
0
17,430
0
17,413
18,279
18,327
0
21,597
21,509
21,516
21,477
21,508
21,541
21,475
11,840
11,742
5,862
5,792
5,753
5,656
5,600
5,505
3,479
3,675
20,714
19,370
18,797
18,326
28,777
28,651
28,670
28,806
28,572
28,493
54,773
59,066
59,678
59,636
68,787
70,184
74,378
76,176
90,813
78,639
77,410
75,848
75,84877,41078,63990,81376,17674,37870,18468,78759,63659,67859,06654,77328,49328,57228,80628,67028,65128,77718,32618,79719,37020,7143,6753,4795,5055,6005,6565,7535,7925,86211,74211,84021,47521,54121,50821,47721,51621,50921,597018,32718,27917,413017,4300020,4209,8602961,0851,1771,4859,4189,4309,0559,1789,1129,1799,0809,2329,4179,57833,47533,61333,96234,00034,60834,81235,26835,33835,63436,04036,42236,98237,70038,48439,30439,99840,78641,54943,46144,93545,10445,78944,9523,9874,3014,4004,2004,2004,0003,8004,0004,3004,6004,5004,7005,1005,4005,6005,6005,5005,4005,4005,4005,2005,3005,3005,3005,30005,200000
       Property Plant Equipment 
0
0
0
4,900
0
4,800
4,900
5,000
4,900
4,900
5,100
5,000
5,000
5,100
5,000
5,000
4,900
4,500
4,200
3,900
4,100
3,800
3,500
3,300
3,500
3,800
3,700
4,000
3,921
3,613
4,505
6,206
7,321
8,635
8,589
8,308
7,698
7,087
6,407
5,520
4,779
4,093
3,583
3,423
3,159
2,876
2,756
2,495
2,351
2,150
2,104
1,747
1,611
1,440
1,282
1,100
951
1,053
986
1,052
929
1,304
1,292
1,285
1,177
1,085
296
140
140
0
0
170
145
145
1,119
1,175
1,220
1,220
1,147
1,162
1,131
1,170
1,210
1,152
1,072
982
909
847
816
727
678
591
503
706
6,132
4,788
4,215
3,844
12,952
12,819
12,837
12,811
12,739
12,638
38,072
37,665
38,277
38,977
46,652
48,265
52,459
54,136
57,276
56,943
57,145
55,867
55,86757,14556,94357,27654,13652,45948,26546,65238,97738,27737,66538,07212,63812,73912,81112,83712,81912,9523,8444,2154,7886,1327065035916787278168479099821,0721,1521,2101,1701,1311,1621,1471,2201,2201,1751,119145145170001401402961,0851,1771,2851,2921,3049291,0529861,0539511,1001,2821,4401,6111,7472,1042,1502,3512,4952,7562,8763,1593,4233,5834,0934,7795,5206,4077,0877,6988,3088,5898,6357,3216,2064,5053,6133,9214,0003,7003,8003,5003,3003,5003,8004,1003,9004,2004,5004,9005,0005,0005,1005,0005,0005,1004,9004,9005,0004,9004,80004,900000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,649,000,000
31,649
31,649,000,000
0
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
0
0
0
0
9,730
7,410
0
0
4,330
4,329
4,329
4,329
4,329
7,562
7,562
7,562
7,562
7,562
7,562
7,562
7,562
0
0
0
0
0
0
0
0
0
0
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,49000000000007,5627,5627,5627,5627,5627,5627,5627,5624,3294,3294,3294,3294,330007,4109,73000007,9267,9267,9267,9267,9267,9267,9267,9267,9267,92631,64931,64931,64931,64931,64931,64931,64931,64931,64931,649031,649,000,00031,64931,649,000,000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
300
0
400
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,488
37,821
36,304
34,786
33,269
31,752
31,625
31,499
31,520
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,880
0
0
12,940
12,939
12,939
12,831
12,823
12,815
12,815
12,800
12,792
12,784
12,776
12,769
12,761
10,768
10,760
4,953
4,945
4,937
4,929
4,922
4,914
2,976
2,969
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
0
010,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,2562,9692,9764,9144,9224,9294,9374,9454,95310,76010,76812,76112,76912,77612,78412,79212,80012,81512,81512,82312,83112,93912,93912,9400012,88000000000000000031,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,52031,49931,62531,75233,26934,78636,30437,82139,488000000000000000000000003004000300000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
836
11,092
11,092
-1
10,992
12,335
23,211
23,133
12,505
12,343
2,109
13,211
17,911
17,911
17,169
18,645
0
8,173
0
0
0
0
0
000008,173018,64517,16917,91117,91113,2112,10912,34312,50523,13323,21112,33510,992-111,09211,092836000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
1,900
0
3,200
3,100
3,800
3,700
3,500
3,300
4,200
4,300
6,200
5,100
5,600
4,900
4,800
4,500
4,200
4,900
4,400
4,100
4,200
3,900
4,400
4,300
6,700
6,299
6,745
12,418
24,542
23,823
20,929
28,110
33,637
31,065
50,016
47,773
46,066
44,807
35,232
22,495
23,443
23,932
24,559
21,381
20,203
20,314
20,568
18,248
18,227
19,175
18,603
18,461
12,100
11,777
13,696
10,640
12,234
11,227
13,248
12,243
10,922
10,875
2,099
1,797
4,330
9,130
0
0
52,240
52,168
52,168
40,283
17,081
25,180
25,180
23,284
18,415
18,779
19,364
7,795
7,808
8,472
7,654
5,245
4,024
3,407
3,109
3,381
3,766
3,413
4,656
12,286
11,172
10,858
10,620
19,823
21,056
20,659
18,833
19,662
18,916
44,371
46,226
47,693
47,304
59,754
86,332
82,069
125,147
142,029
176,866
154,414
149,210
149,210154,414176,866142,029125,14782,06986,33259,75447,30447,69346,22644,37118,91619,66218,83320,65921,05619,82310,62010,85811,17212,2864,6563,4133,7663,3813,1093,4074,0245,2457,6548,4727,8087,79519,36418,77918,41523,28425,18025,18017,08140,28352,16852,16852,240009,1304,3301,7972,09910,87510,92212,24313,24811,22712,23410,64013,69611,77712,10018,46118,60319,17518,22718,24820,56820,31420,20321,38124,55923,93223,44322,49535,23244,80746,06647,77350,01631,06533,63728,11020,92923,82324,54212,4186,7456,2996,7004,3004,4003,9004,2004,1004,4004,9004,2004,5004,8004,9005,6005,1006,2004,3004,2003,3003,5003,7003,8003,1003,20001,900000
   > Total Current Liabilities 
0
0
0
900
0
1,400
1,300
1,600
1,300
1,300
1,300
1,800
1,600
3,800
2,900
3,500
3,000
2,800
2,700
2,700
3,200
2,900
2,800
3,300
2,900
3,200
3,200
4,600
4,153
4,425
7,153
12,686
14,183
10,865
10,359
11,628
9,804
12,377
12,436
11,282
10,197
11,142
7,471
6,709
7,475
8,328
4,848
3,995
4,041
4,576
3,685
4,628
3,917
4,001
6,568
5,188
5,812
6,598
5,125
4,657
3,804
5,983
5,140
3,986
4,109
2,008
1,797
1,510
6,050
0
0
1,480
2,147
2,147
1,366
2,499
1,868
1,868
2,167
2,259
2,385
2,651
3,324
3,154
3,580
2,876
3,711
2,477
1,968
1,775
2,049
2,465
2,572
3,591
5,634
4,965
4,879
6,357
5,207
7,070
6,705
4,981
5,903
5,254
4,814
6,226
7,383
7,004
24,873
51,415
51,562
21,884
16,461
110,045
123,181
118,204
118,204123,181110,04516,46121,88451,56251,41524,8737,0047,3836,2264,8145,2545,9034,9816,7057,0705,2076,3574,8794,9655,6343,5912,5722,4652,0491,7751,9682,4773,7112,8763,5803,1543,3242,6512,3852,2592,1671,8681,8682,4991,3662,1472,1471,480006,0501,5101,7972,0084,1093,9865,1405,9833,8044,6575,1256,5985,8125,1886,5684,0013,9174,6283,6854,5764,0413,9954,8488,3287,4756,7097,47111,14210,19711,28212,43612,3779,80411,62810,35910,86514,18312,6867,1534,4254,1534,6003,2003,2002,9003,3002,8002,9003,2002,7002,7002,8003,0003,5002,9003,8001,6001,8001,3001,3001,3001,6001,3001,4000900000
       Short-term Debt 
0
0
0
200
0
400
400
600
600
600
700
900
1,000
1,100
1,100
1,300
1,300
1,100
1,000
1,000
1,200
1,200
1,100
1,200
1,300
1,400
1,200
1,200
1,100
1,041
986
838
813
970
1,652
1,308
1,197
1,253
1,214
1,298
1,624
1,567
1,332
1,290
1,280
1,511
1,344
1,269
982
873
188
155
116
65
3,195
1,129
1,114
1,224
504
336
335
335
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,547
0
0
0
0
0
0
803
598
606
305
0
0
0
0
0
1,143
1,264
1,251
1,308
1,366
1,123
2,126
2,273
2,332
2,392
1,729
1,509
1,520
1,706
2,223
17,011
45,492
26,352
13,443
18,962
104,165
124,580
46,351
46,351124,580104,16518,96213,44326,35245,49217,0112,2231,7061,5201,5091,7292,3922,3322,2732,1261,1231,3661,3081,2511,2641,143000003056065988030000001,5470000000000000003353353365041,2241,1141,1293,195651161551888739821,2691,3441,5111,2801,2901,3321,5671,6241,2981,2141,2531,1971,3081,6529708138389861,0411,1001,2001,2001,4001,3001,2001,1001,2001,2001,0001,0001,1001,3001,3001,1001,1001,0009007006006006004004000200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,143
0
0
0
0
718
720
722
724
725
0
0
0
0
0
0
32,388
26,352
0
0
96,668
111,388
0
0111,38896,6680026,35232,38800000072572472272071800001,143000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
600
0
800
700
700
500
500
400
600
400
2,500
1,600
1,900
1,400
1,300
1,400
1,400
1,800
1,500
1,400
1,700
1,400
1,600
1,700
2,300
1,851
2,275
4,267
4,000
3,878
1,766
2,049
3,452
3,165
3,130
2,941
2,012
1,936
1,875
1,301
1,271
1,464
1,988
1,833
1,289
2,217
2,464
1,880
1,770
1,840
2,173
1,895
1,901
2,213
4,005
2,058
2,161
2,307
2,844
2,144
0
0
0
0
0
0
0
0
0
0
2,147
0
0
0
1,547
1,365
1,153
1,464
2,003
2,239
2,173
1,659
1,109
1,856
949
578
810
682
714
729
154
1,768
1,261
547
1,447
1,501
1,871
956
5,726
2,296
1,811
1,138
7,783
4,021
2,977
1,678
5,000
9,584
3,772
1,585
2,057
1,743
1,815
1,8151,7432,0571,5853,7729,5845,0001,6782,9774,0217,7831,1381,8112,2965,7269561,8711,5011,4475471,2611,7681547297146828105789491,8561,1091,6592,1732,2392,0031,4641,1531,3651,5470002,14700000000002,1442,8442,3072,1612,0584,0052,2131,9011,8952,1731,8401,7701,8802,4642,2171,2891,8331,9881,4641,2711,3011,8751,9362,0122,9413,1303,1653,4522,0491,7663,8784,0004,2672,2751,8512,3001,7001,6001,4001,7001,4001,5001,8001,4001,4001,3001,4001,9001,6002,5004006004005005007007008000600000
       Other Current Liabilities 
0
0
0
100
0
200
200
300
200
200
200
300
200
200
200
300
300
400
300
300
200
200
300
400
200
200
300
1,100
1,201
1,108
1,900
7,848
1,914
1,376
1,540
2,237
969
1,922
1,356
1,931
1,313
2,463
2,473
2,968
1,947
2,062
1,167
1,437
842
1,096
1,617
2,425
1,211
1,620
1,155
1,907
2,392
1,302
2,345
2,081
1,078
1,131
1,131
2,759
2,333
1,706
1,315
1,510
6,050
0
0
1,480
0
-139,121
-347,634
-243,501
0
1,624
452
859
676
506
1,042
963
185
1,083
1,191
1,203
1,390
965
1,367
1,751
1,843
3,591
4,370
3,714
3,024
4,991
4,084
4,944
3,476
2,649
3,511
3,525
2,167
4,706
5,677
4,781
6,184
5,923
25,210
4,669
-4,086
3,823
-3,142
70,038
70,038-3,1423,823-4,0864,66925,2105,9236,1844,7815,6774,7062,1673,5253,5112,6493,4764,9444,0844,9913,0243,7144,3703,5911,8431,7511,3679651,3901,2031,1911,0831859631,0425066768594521,6240-243,501-347,634-139,12101,480006,0501,5101,3151,7062,3332,7591,1311,1311,0782,0812,3451,3022,3921,9071,1551,6201,2112,4251,6171,0968421,4371,1672,0621,9472,9682,4732,4631,3131,9311,3561,9229692,2371,5401,3761,9147,8481,9001,1081,2011,1003002002004003002002003003004003003002002002003002002002003002002000100000
   > Long-term Liabilities 
0
0
0
1,000
0
1,800
1,800
2,200
2,400
2,200
2,000
2,400
2,700
2,400
2,200
2,100
1,900
2,000
1,800
1,500
1,700
1,500
1,300
900
1,000
1,200
1,100
2,100
2,147
2,321
5,265
11,856
9,640
10,064
17,751
22,009
21,261
37,639
35,337
34,784
34,610
24,090
15,024
16,734
16,457
16,231
16,533
16,208
16,273
15,992
14,563
13,599
15,258
14,602
11,893
6,912
5,965
7,098
5,515
7,577
7,423
7,265
7,103
6,936
6,766
91
482
2,820
3,080
0
0
50,760
0
50,021
38,917
14,582
0
23,312
21,117
16,156
16,394
16,713
4,471
4,654
4,892
4,778
1,534
1,547
1,439
1,334
1,332
1,301
841
1,065
6,652
6,207
5,979
4,263
14,616
13,986
13,954
13,852
13,759
13,662
39,557
40,000
40,310
40,300
34,881
34,917
30,507
103,263
125,568
66,821
31,233
31,006
31,00631,23366,821125,568103,26330,50734,91734,88140,30040,31040,00039,55713,66213,75913,85213,95413,98614,6164,2635,9796,2076,6521,0658411,3011,3321,3341,4391,5471,5344,7784,8924,6544,47116,71316,39416,15621,11723,312014,58238,91750,021050,760003,0802,820482916,7666,9367,1037,2657,4237,5775,5157,0985,9656,91211,89314,60215,25813,59914,56315,99216,27316,20816,53316,23116,45716,73415,02424,09034,61034,78435,33737,63921,26122,00917,75110,0649,64011,8565,2652,3212,1472,1001,1001,2001,0009001,3001,5001,7001,5001,8002,0001,9002,1002,2002,4002,7002,4002,0002,2002,4002,2001,8001,80001,000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,556
4,239
4,307
4,424
3,077
3,077
3,077
3,077
3,077
3,077
13,662
3,077
3,077
3,077
3,077
3,077
0
30,507
0
0
0
0
0
0000030,50703,0773,0773,0773,0773,07713,6623,0773,0773,0773,0773,0773,0774,4244,3074,2393,556000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
0
0
0
0
0
0
0
000000010,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,2560000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
10,200
0
17,800
15,500
13,200
10,700
8,400
18,400
15,800
13,100
24,300
22,700
19,500
16,300
12,500
9,700
5,600
1,800
11,400
8,100
12,000
9,300
6,600
9,900
7,000
32,589
28,602
72,362
63,432
59,487
54,172
45,213
37,401
31,031
12,579
11,878
5,896
5,066
26,332
39,768
33,479
53,184
48,714
46,002
49,762
45,096
39,802
34,175
30,571
31,908
4,382
1,484
5,367
9,841
23,777
20,868
16,240
13,021
9,465
6,941
-3,772
-5,404
1,978
2,733
7,150
12,940
0
0
-29,500
0
-14,221
-9,021
11,338
0
3,437
13,088
15,663
12,714
8,897
21,484
18,228
9,723
6,648
9,861
9,757
7,731
11,290
8,339
6,853
8,474
4,961
22,630
18,132
14,593
33,482
29,638
24,619
18,857
34,012
28,619
23,755
25,397
61,539
53,291
45,577
36,080
22,447
19,143
-12,386
-32,065
-56,510
-46,101
-50,973
-50,973-46,101-56,510-32,065-12,38619,14322,44736,08045,57753,29161,53925,39723,75528,61934,01218,85724,61929,63833,48214,59318,13222,6304,9618,4746,8538,33911,2907,7319,7579,8616,6489,72318,22821,4848,89712,71415,66313,0883,437011,338-9,021-14,2210-29,5000012,9407,1502,7331,978-5,404-3,7726,9419,46513,02116,24020,86823,7779,8415,3671,4844,38231,90830,57134,17539,80245,09649,76246,00248,71453,18433,47939,76826,3325,0665,89611,87812,57931,03137,40145,21354,17259,48763,43272,36228,60232,5897,0009,9006,6009,30012,0008,10011,4001,8005,6009,70012,50016,30019,50022,70024,30013,10015,80018,4008,40010,70013,20015,50017,800010,200000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,000
98,100
126,805
126,895
198,498
200,968
203,038
203,355
201,146
441
442
442
502
506
506
584
662
662
816
816
816
856
856
856
856
857
985
99
99
109
131
198
198
198
198
200
200
202
204
207
207
450
670
0
0
1,020
0
1,825
1,872
1,872
0
1,992
57
59
59
59
111
111
165
165
85
93
95
165
165
165
323
328
99
99
99
186
186
187
187
249
249
249
271
361
361
361
361
361
361
361
361
361
362
362
362362361361361361361361361361361271249249249187187186186999999328323165165165959385165165111111595959571,99201,8721,8721,82501,020006704502072072042022002001981981981981311099999985857856856856856816816816662662584506506502442442441201,146203,355203,038200,968198,498126,895126,80598,10098,00000000000000000000000000000
   Retained Earnings Total Equity00000-257,811-254,264-239,774-229,460-220,846-211,631-202,857-196,810-191,391-185,197-179,7020000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-400
0
-400
-400
-1,400
-1,400
-1,400
-1,400
-2,900
-2,900
-2,900
-2,900
-4,700
-4,700
-5,400
-5,800
-6,200
-6,600
-7,000
-7,300
-6,200
-6,200
-6,200
-12,200
-12,300
-11
-3
-271
-13,276
-13,504
-13,737
-13,978
-12,015
-12,015
-12,015
-10,973
-11,062
-750,000,000
-12,015
-11,062
-13,482
-13,482
-13,482
-13,482
-13,654
-13,654
-13,654
55
-21
24
40
20
-39
-15,018
-15,018
6
-15,550
-15,550
-15,550
-15,550
-16,055
-16,055
0
-4,959
-180
-390
0
0
-160
-473
-65
-85
-178
-478
-19,425
-10,032
-2,127
-604
-91
-29,279
-26,036
-932
-14,302
-15,106
-13,781
-1,170
-1,170
0
0
-1,528
-1,528
-10,259
-9,090
-8,158
-8,454
-8,722
-8,780
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000-8,780-8,722-8,454-8,158-9,090-10,259-1,528-1,52800-1,170-1,170-13,781-15,106-14,302-932-26,036-29,279-91-604-2,127-10,032-19,425-478-178-85-65-473-16000-390-180-4,9590-16,055-16,055-15,550-15,550-15,550-15,5506-15,018-15,018-39204024-2155-13,654-13,654-13,654-13,482-13,482-13,482-13,482-11,062-12,015-750,000,000-11,062-10,973-12,015-12,015-12,015-13,978-13,737-13,504-13,276-271-3-11-12,300-12,200-6,200-6,200-6,200-7,300-7,000-6,600-6,200-5,800-5,400-4,700-4,700-2,900-2,900-2,900-2,900-1,400-1,400-1,400-1,400-400-4000-400000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
414,467
414,566
168,509
170,968
172,015
195,895
0
0
198,372
218,960
219,761
220,316
227,983
272,809
273,776
274,676
275,493
276,350
276,593
0
0
0
0
0
00000276,593276,350275,493274,676273,776272,809227,983220,316219,761218,960198,37200195,895172,015170,968168,509414,566414,46700000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
19,500
0
31,100
31,000
31,000
31,000
31,100
43,300
43,400
43,600
71,200
73,100
73,100
73,400
73,400
73,400
73,400
73,400
86,100
86,200
88,500
88,500
91,700
12,300
12,400
12,607
12,823
13,047
13,276
13,504
13,737
13,978
214,942
214,977
202,963
207,035
207,139
207,139
235,242
249,380
249,399
273,808
273,788
273,800
279,745
279,751
279,751
279,752
279,772
284,668
285,888
286,200
289,324
297,572
315,628
315,744
316,196
316,390
316,629
316,766
316,900
317,050
317,119
322,162
326,170
333,190
0
0
353,610
0
371,169
363,805
364,869
0
363,451
378,761
375,895
375,177
374,472
390,858
389,977
390,918
391,097
400,851
401,518
401,842
408,465
408,564
408,684
414,467
414,566
168,509
170,968
172,015
195,895
196,761
197,510
198,372
218,960
219,761
220,316
227,983
272,809
273,776
274,676
275,493
276,350
276,593
276,225
276,393
276,969
278,391
279,000
279,000278,391276,969276,393276,225276,593276,350275,493274,676273,776272,809227,983220,316219,761218,960198,372197,510196,761195,895172,015170,968168,509414,566414,467408,684408,564408,465401,842401,518400,851391,097390,918389,977390,858374,472375,177375,895378,761363,4510364,869363,805371,1690353,61000333,190326,170322,162317,119317,050316,900316,766316,629316,390316,196315,744315,628297,572289,324286,200285,888284,668279,772279,752279,751279,751279,745273,800273,788273,808249,399249,380235,242207,139207,139207,035202,963214,977214,94213,97813,73713,50413,27613,04712,82312,60712,40012,30091,70088,50088,50086,20086,10073,40073,40073,40073,40073,40073,10073,10071,20043,60043,40043,30031,10031,00031,00031,00031,100019,500000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,529
Cost of Revenue-33,770
Gross Profit-29,241-29,241
 
Operating Income (+$)
Gross Profit-29,241
Operating Expense-11,649
Operating Income-40,890-40,890
 
Operating Expense (+$)
Research Development33,770
Selling General Administrative11,649
Selling And Marketing Expenses972
Operating Expense11,64946,391
 
Net Interest Income (+$)
Interest Income125
Interest Expense-2,626
Other Finance Cost-1,450
Net Interest Income-1,051
 
Pretax Income (+$)
Operating Income-40,890
Net Interest Income-1,051
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-69,045-12,735
EBIT - interestExpense = -43,516
-69,045
-66,419
Interest Expense2,626
Earnings Before Interest and Taxes (EBIT)-40,890-66,419
Earnings Before Interest and Taxes (EBITDA)-39,918
 
After tax Income (+$)
Income Before Tax-69,045
Tax Provision-0
Net Income From Continuing Ops-59,512-69,045
Net Income-69,045
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses45,419
Total Other Income/Expenses Net-28,1551,051
 

Technical Analysis of Armata Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Armata Pharmaceuticals Inc. The general trend of Armata Pharmaceuticals Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Armata Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Armata Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2.2 < 2.2 < 2.2.

The bearish price targets are: 1.93 > 1.9 > 1.87.

Tweet this
Armata Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Armata Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Armata Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Armata Pharmaceuticals Inc. The current macd is -0.04104725.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Armata Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Armata Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Armata Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Armata Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartArmata Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Armata Pharmaceuticals Inc. The current adx is 29.72.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Armata Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Armata Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Armata Pharmaceuticals Inc. The current sar is 2.83359329.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Armata Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Armata Pharmaceuticals Inc. The current rsi is 47.47. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Armata Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartArmata Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Armata Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Armata Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Armata Pharmaceuticals Inc Daily Stochastic Oscillator ChartArmata Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Armata Pharmaceuticals Inc. The current cci is -59.63239625.

Armata Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartArmata Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Armata Pharmaceuticals Inc. The current cmo is -5.0213378.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Armata Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartArmata Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Armata Pharmaceuticals Inc. The current willr is -72.44897959.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Armata Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Armata Pharmaceuticals Inc Daily Williams %R ChartArmata Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Armata Pharmaceuticals Inc. The current atr is 0.17609452.

Armata Pharmaceuticals Inc Daily Average True Range (ATR) ChartArmata Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Armata Pharmaceuticals Inc. The current obv is 7,656,638.

Armata Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartArmata Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Armata Pharmaceuticals Inc. The current mfi is 55.66.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Armata Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartArmata Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Armata Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Armata Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Armata Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.470
Ma 20Greater thanMa 502.324
Ma 50Greater thanMa 1002.324
Ma 100Greater thanMa 2002.470
OpenGreater thanClose2.199
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Armata Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Armata Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Armata Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Armata Pharmaceuticals Inc

I send you an email if I find something interesting about Armata Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Armata Pharmaceuticals Inc.

Receive notifications about Armata Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.